Literature DB >> 26171685

Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study.

Edith M Koehler1, Elisabeth P C Plompen1, Jeoffrey N L Schouten2, Bettina E Hansen1,3, Sarwa Darwish Murad1, Pavel Taimr1, Frank W G Leebeek4, Albert Hofman5, Bruno H Stricker5, Laurent Castera6, Harry L A Janssen1,7.   

Abstract

UNLABELLED: Given that little is known about the prevalence of, and factors associated with, liver fibrosis in the general population, we aimed to investigate this in a large, well-characterized cohort by means of transient elastography (TE). This study was part of the Rotterdam Study, a population-based study among individuals ≥45 years. All participants underwent abdominal ultrasound and TE. Liver stiffness measurement (LSM) ≥8.0 kilopascals (kPa) was used as a cutoff suggesting clinically relevant fibrosis. Of 3,041 participants (age, 66.0 ± 7.6 years) with reliable LSM, 169 (5.6%) participants had LSM ≥8.0 kPa. Age (odds ratio [OR]: 2.40; 95% confidence interval [CI]: 1.72-3.36; P < 0.001), alanine aminotransferase (ALT; OR, 1.24; 95% CI: 1.12-1.38; P < 0.001), smoking (OR, 1.77; 95% CI: 1.16-2.70; P = 0.008), spleen size (OR, 1.23; 95% CI: 1.09-1.40; P = 0.001), hepatitis B surface antigen, or anti-hepatitis C virus positivity (OR, 5.38; 95% CI: 1.60-18.0; P = 0.006), and combined presence of diabetes mellitus (DM) and steatosis (OR, 5.20; 95% CI: 3.01-8.98; P < 0.001 for combined presence) were associated with LSM ≥8.0 kPa in multivariable analyses. The adjusted predicted probability of LSM ≥8.0 kPa increased per age decade, with probabilities ranging from 1.4% (0.9-3.6) in participants ages 50-60 years to 9.9% (6.8-14.5) in participants >80 years. Participants with both DM and steatosis had the highest probabilities of LSM ≥8.0 kPa (overall probability: 17.2% [12.5-23.4]; this probability did not increase with age [P = 0.8]).
CONCLUSION: In this large population-based study of older adults, LSM ≥8.0 kPa, suggestive of clinically relevant fibrosis, was present in 5.6% and was strongly associated with steatosis and DM. In the context of an aging population and an increased prevalence of DM and obesity, this study illustrates that liver fibrosis may become a more prominent public health issue in the near future.
© 2015 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2015        PMID: 26171685     DOI: 10.1002/hep.27981

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  80 in total

Review 1.  The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View.

Authors:  Christina C Lindenmeyer; Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2018-02       Impact factor: 6.126

Review 2.  Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis.

Authors:  P Wainwright; E Scorletti; C D Byrne
Journal:  Curr Diab Rep       Date:  2017-04       Impact factor: 4.810

Review 3.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

Review 4.  NAFLD and diabetes mellitus.

Authors:  Herbert Tilg; Alexander R Moschen; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-12       Impact factor: 46.802

5.  High Prevalence of Hepatic Fibrosis, Measured by Elastography, in a Population-Based Study of Mexican Americans.

Authors:  Gordon P Watt; Miryoung Lee; Jen-Jung Pan; Michael B Fallon; Rohit Loomba; Laura Beretta; Joseph B McCormick; Susan P Fisher-Hoch
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-11       Impact factor: 11.382

Review 6.  Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools.

Authors:  Yan Wang; Jin-Lin Hou
Journal:  Hepatol Int       Date:  2016-01-07       Impact factor: 6.047

7.  Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database.

Authors:  Alina M Allen; Holly K Van Houten; Lindsey R Sangaralingham; Jayant A Talwalkar; Rozalina G McCoy
Journal:  Hepatology       Date:  2018-09-20       Impact factor: 17.425

8.  Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.

Authors:  Abdel Aziz Shaheen; Kiarash Riazi; Alexandra Medellin; Deepak Bhayana; Gilaad G Kaplan; Jason Jiang; Roy Park; Wendy Schaufert; Kelly W Burak; Monica Sargious; Mark G Swain
Journal:  CMAJ Open       Date:  2020-05-15

9.  Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug-metabolite atlas.

Authors:  Jun Liu; Lies Lahousse; Michel G Nivard; Mariska Bot; Lianmin Chen; Jan Bert van Klinken; Carisha S Thesing; Marian Beekman; Erik Ben van den Akker; Roderick C Slieker; Eveline Waterham; Carla J H van der Kallen; Irene de Boer; Ruifang Li-Gao; Dina Vojinovic; Najaf Amin; Djawad Radjabzadeh; Robert Kraaij; Louise J M Alferink; Sarwa Darwish Murad; André G Uitterlinden; Gonneke Willemsen; Rene Pool; Yuri Milaneschi; Diana van Heemst; H Eka D Suchiman; Femke Rutters; Petra J M Elders; Joline W J Beulens; Amber A W A van der Heijden; Marleen M J van Greevenbroek; Ilja C W Arts; Gerrit L J Onderwater; Arn M J M van den Maagdenberg; Dennis O Mook-Kanamori; Thomas Hankemeier; Gisela M Terwindt; Coen D A Stehouwer; Johanna M Geleijnse; Leen M 't Hart; P Eline Slagboom; Ko Willems van Dijk; Alexandra Zhernakova; Jingyuan Fu; Brenda W J H Penninx; Dorret I Boomsma; Ayşe Demirkan; Bruno H C Stricker; Cornelia M van Duijn
Journal:  Nat Med       Date:  2020-01-13       Impact factor: 53.440

10.  Occult liver disease burden: Analysis from a large general practitioners' database.

Authors:  Andrea Martini; Elena Ceranto; Angelo Gatta; Paolo Angeli; Patrizia Pontisso
Journal:  United European Gastroenterol J       Date:  2017-02-26       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.